Clinical trials
Progression clinical trials
Below are recruiting progression clinical trials, each written for real people, not researchers. We’re tracking 721 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07606872Enrolling by invitation
Testing a diabetes score to guide treatment reversal
This study tests a new scoring system to help people with type 2 diabetes understand their condition better and potentially reverse or improve it. You'll use a digital platform to track blood sugar, answer health questions, and have blood tests to see if the system helps guide your treatment plan.
Manchester, EnglandAges 18 years+ - NCT07538843Recruiting
Darolutamide Plus Hormone Therapy for Prostate Cancer in China
This study watches how well a drug called darolutamide works when combined with hormone therapy for men with prostate cancer that has returned after previous treatment. The goal is to understand if this combination helps prevent cancer spread and is safe to use.
Multiple LocationsAges 18 years+ - NCT07036341Recruiting
Recovering after a hip fracture: protein and exercise
This study tests whether extra protein in your diet combined with exercise can help you recover better after a hip fracture, improving your bone and muscle health and quality of life.
ArnhemAges 65 years+ - NCT06319027RecruitingPhase 2
Can brain scans help predict glioblastoma progression?
This trial is testing whether certain details on brain scans can help doctors better predict how brain cancer (glioblastoma) will progress. You may be eligible if you are newly diagnosed with this type of cancer and plan to receive standard treatment.
Birmingham, AlabamaAges 18 years+ - NCT07166094RecruitingPhase 3
Rina-S vs standard therapy for advanced endometrial cancer
This trial tests a new drug called Rina-S (an antibody-drug conjugate) against standard treatments for advanced endometrial cancer that has returned after prior therapy. It may be an option if you have had at least 1 but no more than 3 prior treatments, including platinum chemo and immunotherapy.
Mobile, AlabamaAges 18 years+ - NCT06047171RecruitingPhase 2
Testing ALE.F02 for new kidney inflammation from vasculitis
This trial tests a new medicine called ALE.F02 for people newly diagnosed with a type of kidney inflammation called rapidly progressive glomerulonephritis (RPGN) caused by ANCA vasculitis. The goal is to see if it can help rescue kidney function.
PragueAges 18 years+ - NCT07764081Recruiting
Coronary artery aneurysm care and outcomes
This study looks at how coronary artery aneurysms (a bulging or ballooning of the heart's blood vessel wall) are managed and how they affect people over time. It aims to improve future care by tracking treatment and health results.
Nanjing, JiangsuAges 18–80 - NCT07762573Recruiting
Predicting COPD progression with dynamic chest x-rays
This study looks at whether a special type of chest x-ray (called dynamic chest radiography) can help predict how chronic obstructive pulmonary disease (COPD) might progress. It may help doctors better understand the disease and plan treatment.
Guangzhou, GuangdongAges 30–85 - NCT07150806RecruitingPhase 1/Phase 2
RYZ101 for progressive or recurrent meningioma
This trial is testing an investigational drug, RYZ101, for people with a type of brain tumor called meningioma that has grown back or not responded to other treatments. The goal is to see if RYZ101 can help stop the tumor from growing, and to check its safety. It might be an option if you have already had surgery or radiation.
Columbus, OhioAges 18 years+ - NCT07420907Recruiting
Tracking heart health over time
This study uses a wearable patch to monitor heart-related signs in people with heart conditions. It aims to learn more about how these conditions progress, which could help improve future care.
Chicago, IllinoisAges 18 years+ - NCT07544992RecruitingPhase 1
CAR T Cells for Recurrent High-Grade Brain Tumors
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Duarte, CaliforniaAges 18 years+ - NCT07743996Recruiting
Emotional and social experiences with fibrosis medications
This study looks at how people with pulmonary fibrosis feel emotionally and socially while taking antifibrotic medications like nintedanib or pirfenidone. It aims to understand the real-world impact of these treatments on daily life.
TokyoAges 40 years+ - NCT05837884Recruiting
Predicting who may develop myeloma in high-risk people
This study tries to predict which people at higher risk will develop myeloma (a blood cancer) and how quickly. It may help doctors spot problems earlier in people with family history and offer better follow-up.
BeershebaAges 30 years+ - NCT07214571RecruitingPhase 2
Study of S-337395 for RSV in high-risk adults
This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.
Los Angeles, CaliforniaAges 18 years+ - NCT07342478RecruitingPhase 3
Comparing two BTK inhibitors for CLL/SLL after prior treatment
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
Skokie, IllinoisAges 18 years+ - NCT07754097Recruiting
Tracking your health at home for chronic kidney disease
This study tests if regularly tracking your blood pressure, diet, and medications through a mobile app can help monitor kidney disease progression. It aims to see if this self-management approach helps you stay healthier.
Daejeon, DJAges 19–84 - NCT07383649RecruitingPhase 2
Anti-CMV therapy for breast cancer with brain metastases
This trial tests a treatment targeting a common virus (CMV) in breast cancer that has spread to the brain. The goal is to see if anti-CMV therapy can shrink or slow these brain tumors.
Houston, TexasAges 18 years+ - NCT07741968Recruiting
Online program to ease fear of cancer returning
This study tests an online program designed to help women with advanced or certain types of breast or gynecologic cancer manage their fear of the disease progressing or returning. The program aims to reduce anxiety and improve quality of life.
Arcadia, CaliforniaAges 18 years+ - NCT06943872RecruitingPhase 3
Comparing new treatments for relapsed CLL or SLL
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
Laguna Hills, CaliforniaAges 18 years+ - NCT06951217RecruitingPhase 2
Long-term safety study of an inhaled drug for lung scarring
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
Birmingham, AlabamaAges 18 years+ - NCT07652762RecruitingPhase 1
IN10018 and dalpiciclib for progressive meningioma
This trial tests a combination of two oral drugs, IN10018 and dalpiciclib, for people with progressive meningioma (a type of brain tumor) that has not responded to standard treatments. The goal is to see if this combination can help shrink or slow the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07752030Enrolling by invitation
Measuring treatment effects in cerebral palsy
This study looks at how well different treatments work for people with cerebral palsy. It may help doctors understand which treatments are best for improving walking and movement.
Omaha, NebraskaAges 16–30 - NCT07425574Recruiting
Study on how Stargardt eye conditions progress in children and adults
This study observes how Stargardt disease and similar eye conditions change over time in children and adults. It aims to learn more about the disease progression to help develop future treatments.
Phoenix, ArizonaAges 6 years+ - NCT07173829Recruiting
Study of why glioblastoma comes back
This trial collects tumor samples to study what causes glioblastoma to return. It may help scientists find better treatments.
BordeauxAges 18 years+
Hear when a new Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progression?
- Yes. Clin2 currently lists 721 recruiting progression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.